Paediatric therapy-related acute myeloid leukaemia (t-AML) is rare and the outcome is poor. While allogeneic haematopoietic stem cell transplantation (HSCT) is generally the accepted modality of treatment, data regarding salvage chemotherapy, remission induction, conditioning regimens, transplant-related mortality and outcome is scarce. Between 2000 and2016, 36 children with t-AML were treated in seven UK paediatric HSCT centres. The most common salvage protocol for remission induction was FLAG with or without idarubicin and 28 patients were in complete morphological remission prior to BMT. Only 12 patients survived (33%). Transplant-related mortality (TRM) was the leading cause of death.
Introduction
Therapy-related acute myeloid leukaemia (t-AML) is a well-recognised clinical subtype of AML [1] . t-AML occurring in adults is usually associated with inferior outcome compare with de novo AML [2] [3] [4] . Although more children now survive their first cancer, data on paediatric outcomes of t-AML is limited, outcome historically has been very poor (15-30%) and generally allogeneic HSCT is the treatment modality of choice [5] [6] [7] . Furthermore, it is not known whether the inferior outcome is due to disease relapse or transplant-related mortality. Our aim herein was to retrospectively assess the outcome of children who were diagnosed with t-AML and received HSCT in a dedicated JACIE accredited paediatric UK transplant centre.
Patients and methods
A survey questionnaire was sent to all UK Paediatric HSCT centres asking centres to identify children (0-18 years) who were transplanted in their centres for a diagnosis of t-AML from January 2000-January 2016. Definition of t-AML was according to the WHO criteria [1] . Electronic data collection for patient demographics, HSCT characteristics and outcomes were collected.
Statistical analysis
SAS software was used to carry out the statistical analyses. Time to event (relapse or death) and the probability of event free survival (EFS) and overall survival (OS) for different endpoints was determined using Kaplan-Meier curves. The association between pairs of categorical variables was evaluated using Fisher's exact test. A two tailed p value of <0.05 was considered to be statistically significant. The cumulative incidence of relapse and treatment-related mortality was estimated taking into account the competing risks of other events. Given the small number of survivors, a Cox proportional hazard survival model was not possible and the impact of different variables on survival was descriptive. Transplant-related mortality (TRM) was defined as any death in remission.
Results
Seven UK paediatric HSCT centres participated in the study and sent data regarding children who received HSCT for t-AML. Total number of patients was 37, however, one child with t-AML and a previous diagnosis of neuroblastoma died within 2 days of the diagnosis of t-AML and did not receive HSCT and was therefore excluded from the study. Median time from the original diagnosis to the diagnosis of t-AML was 3.8 years (1-9.5 years).
Cytogenetics results were available in 30 patients and 23 of them had poor risk cytogenetics (p = 0.02) including MLL rearrangements, monosomy 7 and complex karyotype ( Table 1) . Fourteen patients had received radiotherapy as part of their treatment for first cancer. Fludarabine, high dose cytarabine, and granulocyte colony stimulating factor (FLAG) with or without idarubicin (FLAG-Ida) was the most common salvage regimen prior to HSCT. Remission status prior to HSCT was known in 28 patients, 24 were in complete remission (CR) prior to HSCT leading to a statistically significant likelihood to enter remission prior to HSCT (p = 0.001). The majority (28 patients) received a graft from an unrelated donor (18 from an unrelated adult donor and 10 from a cord unrelated progenitor stem cell source). Conditioning regimens varied among centresoverall 28 patients received myeloablative regimens (TBI based in 8 patients) and 6 patients received reduced intensity conditioning. All patients received cyclosporine A (CSA) as GVHD prophylaxis. Recipients of unrelated donor graft received campath 1 H as serotherapy and recipients of cord progenitor stem cells received mycophenolate mofetil 
Survival
One patient was lost to follow up, therefore, survival outcome was available on 35 patients. At a median follow up of 7.3 years (range 2.1-16.1) 12 patients are long term survivors (OS = 34%) and 23 patients have died. Thirteen out of the 23 patients (56%) died from TRM and 10 patients (44%) died from disease relapse giving an overall TRM rate of 37% and a relapse rate of 29%. All patients who relapsed died, therefore EFS and OS was the same (Fig. 1 ). Potential variables that had an impact on survival were as follows: (1) There were 17 patients with t-AML post a solid tumour and 11 of them died post HSCT and 12 out of the 18 patients with t-AML post haematological/lymphoid malignancy have died post HSCT. Eighteen patients received HSCT from a living UD and 11 died (TRM = 5, relapse = 6). Ten patients received unrelated cord progenitor stem cells and eight died post HSCT (TRM = 6, relapse = 2). Eight patients received matched sibling donor and four died (TRM = 2, relapse = 2). Twenty-three patients had poor risk cytogenetics. Five out of nine patients with MLL gene rearrangement died, three from TRM and two from relapsed disease. Five out of nine patients with monosomy seven died, four from TRM and one from relapsed disease. All patients with complex cytogenetics (n = 5) died, three from TRM and two from relapsed disease. Therefore, 8 out of 23 patients with poor risk cytogenetics are alive compared to 4 out of 12 patients without poor risk cytogenetics (P = NS). As for the conditioning regimens; of nine patients who were conditioned with fludarabine, treosulphan and thiotepa (FTT) or fludarabine and treosulphan (FT), seven have died, four from TRM and three from relapsed disease. Of those who were conditioned with BU/CY/Mel (n = 8), five have died, four from TRM and one from relapsed disease. Eight patients were conditioned with CY/TBI and four have died, two from TRM and two from relapsed disease and six patients were conditioned with FLU/Mel and four have died one from TRM and three from relapsed disease. Those who did not achieve remission prior to BMT (n = 4) three of them died post BMT, two from TRM and one from relapsed disease. Seventeen patients had acute GVHD, grade I in four patients (one died from TRM), grade II in six patients (two died from relapse and two died from TRM), grade III in two patients and both died from TRM and grade IV in five patients (two died from TRM and one died from relapse). Therefore, seven patients with GVHD died from TRM, five from multi organ failure and two from sepsis. The cause of TRM in the remaining six patients who did not have GVHD were as follows; pneumonitis with respiratory failure (n = 3), adeno virus infection (n = 1), pseudomans aeruginosa sepsis (n = 1) and multi organ failure (n = 1).
Discussion
In this multi-centre retrospective paediatric study for t-AML and HSCT, we found that the majority of t-AML is associated with poor risk cytogenetics. However, remission induction and maintaining remission to proceed to HSCT was possible in the majority of patients. Furthermore, the main cause of death was TRM rather than relapse and a survival of 34% was similar to other published reports of t-AML [3] [4] [5] [6] [7] [8] .
Among 2589 children with cancer treated at MD Anderson, Aguilera et al. [9] reported 22 children with t-AML who were treated differently with some subtle differences in their outcome. Three patients received supportive care only. Group 1 (n = 5) underwent HSCT without induction chemotherapy. Group 2 (n = 5) patients received AML-type chemotherapy and HSCT post remission (n = 5). Group 3 (n = 4) received HSCT as salvage therapy. The respective 2-year survival rates for groups 1, 2, and 3 were 20%, 40%, and 25% (P = 0.85) [9] . Due to the small number of patients there was no statistical significance difference in their outcome. However, group 2 which included patients who received AML-type chemotherapy followed by HSCT had the best outcome. In our study all patients with t-AML were treated following the same principle since post HSCT outcome is generally superior if patients achieve good remission prior to HSCT and achieving remission prior to HSCT was possible in the majority of our patients. t-AML is recognised as an independent poor prognostic factor among AML [10] . Nonetheless, in our study, the main cause of death was TRM rather than disease relapse. We acknowledge the fact that TRM is a competing risk for disease relapse and it is unknown how many of the patients who died from TRM would have relapsed if they lived longer. Woodard et al. [11] analysed the results of allogeneic HSCT in 38 children with t-AML to determine which factors, if any, affected outcome. Three-year OS and EFS were the same (15.4 ± 5.8%) and a very high 3-year TRM (59.6 ± 8.4%) [11] . This high TRM incidence was similarly observed in our study. A large adult study analysed outcomes in 868 persons with t-AML (n = 545) or t-MDS (n = 323) receiving allogeneic transplants from 1990 to 2004. EFS and OS were 32% (95% CI, 29-36) and 37% (34-41) at 1 year and 21% (18-24) and 22% (19-26) at 5 years, respectively. In a In multivariate analysis, 4 risk factors had adverse impacts on EFS and OS: (1) age older than 35 years; (2) poor risk cytogenetics; (3) t-AML not in remission or advanced t-MDS; and (4) donor other than an HLA-identical sibling or a partially or well-matched unrelated donor [12] . In our paediatric study survival statistical model was not possible due to small number of patients.
While it is not possible to change the t-AML aggressive disease biology and high risk features, there may be some measures that could be taken to reduce TRM. We believe that this high TRM incidence was caused by the heavily pre-treated status of these patients since all patients received multiple cycles of chemotherapy for their original cancer and strong salvage chemotherapy for the t-AML, FLAG or FLAG/Ida. Furthermore, almost all patients received two cycles of FLAG prior to HSCT but the majority were in remission after the first cycle. Therefore, provided a suitable donor is available and the patient is in remission, proceeding to HSCT after one cycle of FLAG/Ida may lead to a reduction in TRM.
Another factor that may have contributed to the high incidence of TRM was the choice of the conditioning regimen. Our observation suggests the children who received a fully myeloablative conditioning regimen such as BU/CY/Mel have a high TRM rate (50%), while those who received a reduced intensity conditioning regimen such as FLU/Mel had a high relapse rate (50%). It is possible that a reduced toxicity rather than a reduced intensity regimen such as BU/FLU may lead to a reduction of TRM while preserving anti leukaemic activity [13] [14] [15] . Within the United Kingdom, we plan to investigate this approach prospectively.
We acknowledge the limitation of our study, in particular, the retrospective design and that survival model statistical analysis was not possible due to the limited number of patients. However, our observations suggests that TRM is the main cause of death in this very high risk paediatric malignancy and potential measures such as reduction of salvage chemotherapy after achieving remission and a careful choice of the conditioning regimen may be helpful in reducing TRM. Larger prospective studies are required.
